IMMUNITYBIO, INC. Deferred Revenue (Non-Current)
IMMUNITYBIO, INC. (IBRX) had Deferred Revenue (Non-Current) of $166.00 thousand as of 2017-12-31, per its 10-K filed 2018-03-12.
Discontinued › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredRevenueNoncurrent · last filed 2018-03-12
- 2017-12-31: Deferred Revenue, Noncurrent $166.00K.
- 2017-03-31: Deferred Revenue, Noncurrent $182.00K.
- 2016-12-31: Deferred Revenue, Noncurrent $187.00K.
- 2016-09-30: Deferred Revenue, Noncurrent $192.00K.
| Period end | Deferred Revenue, Noncurrent |
|---|---|
| 2017-12-31 | $166.00K 10-K · filed 2018-03-12 |
| 2017-03-31 | $182.00K 10-Q · filed 2017-05-08 |
| 2016-12-31 | $187.00K 10-K · filed 2018-03-12 |
| 2016-09-30 | $192.00K 10-Q · filed 2016-11-10 |
| 2016-06-30 | $197.00K 10-Q · filed 2016-08-15 |
| 2016-03-31 | $203.00K 10-Q · filed 2016-05-16 |
| 2015-12-31 | $228.00K 10-K · filed 2017-03-15 |
| 2014-12-31 | $521.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |